NORVASC® (amlodipine besylate) Tablets Warnings

Print this page | Cancel

New user?

Why Register?

----------------------------------------------

Returning user?

----------------------------------------------

Forgot Password?

Registration FAQs

Patient Education Materials

Patient Assistance Programs

Clinical Trials

Pipeline

Pfizer Contacts

Pfizer Medical Information
(Search Medical Responses)

WyethHCP.com
(Access Wyeth for Professionals)

Explore Other Online Resources

ppn-vr-sso-links.htm

To report an adverse event or to speak to a member of Pfizer Medical Information, please call 1-800-438-1985

Prescribing Information

NORVASC^® (amlodipine besylate) Tablets
Warnings


	Return to the NORVASC Product Center

Increased Angina and/or Myocardial Infarction: Rarely, patients, particularly those with severe obstructive coronary artery disease, have developed documented increased frequency, duration and/or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. The mechanism of this effect has not been elucidated.

NORVASC Safety Information

Important Safety Information

NORVASC is indicated for the treatment of hypertension and angina.

In clinical trials, the most common side effects versus placebo were edema (8.3% vs 2.4%), headache (7.3% vs 7.8%), fatigue (4.5% vs 2.8%), and dizziness (3.2% vs 3.4%).

Generally CCBs should be used with caution in patients with heart failure. In studies with NORVASC, there has been no evidence of worsened heart failure.

Please see full prescribing information.

NORVASC ^® (amlodipine besylate)